Clinical Trials Logo

Clinical Trial Summary

The aim of this prospective research project is to better understand vulvovaginal cGVHD to improve care of allografted women. The expected outcomes include better knowledge of the incidence and manifestations of vulvovaginal cGVHD, risk factors, response to treatments and impact on sexual health of allotransplanted female patients. The knowledge acquired will allow transplant clinicians to make more precise recommendations for gynecological management of future allografted women.


Clinical Trial Description

The invetigators plan to recruit 100 women who will be evaluated 9 times over a period of 2 years (before allograft, at + 3 months, +6 months, +9 months, +12 months, +15 months, +18 months, +21 months, and +24 months +/- 14 days). If a new diagnosis of cGVHD is made between 2 visits, an additional gynecological examination will be performed. Visits by the Hôpital Maisonneuve-Rosemont Hospital transplant team will include a physical examination to assess for the presence of cGVHD using the NIH criteria. The FACT-BMT quality of life questionnaire will also be completed before the allograft, at 3 months and 6 months after transplant. If cGVHD is diagnosed, the participants will also have to complete two questionnaires specific to cGVHD (Lee Scale for cGVHD, Patient self-assessment of cGVHD) at diagnosis and then at + 6, +12, +18 and +24 months from day 0 of allograft. Assessments by CHUM gynecologists will take place before the allograft, then at +3, +6, +12, +18 and +24 months from day 0 of the allograft and will include: a vulvar/vaginal examination, a sample for HPV testing and sexual health questionnaires to be completed (Personal assessment of intimacy within relationships - PAIR, Female Sexual Function Index - FSFI , Female Sexual Distress Scale-Revised - FSDS-R). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06279676
Study type Observational [Patient Registry]
Source Ciusss de L'Est de l'Île de Montréal
Contact Michel-Olivier Gratton
Phone 514-252-3400
Email mogratton.hmr@ssss.gouv.qc.ca
Status Not yet recruiting
Phase
Start date July 2024
Completion date December 2028

See also
  Status Clinical Trial Phase
Completed NCT03042676 - Electronic Database for the Follow up of the ATG_FamilyStudy
Recruiting NCT05401955 - Physiotherapy and Therapeutic Exercise Program in Graft-versus-host Disease (GvHD) N/A
Recruiting NCT04932564 - Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant Phase 2
Not yet recruiting NCT06169722 - TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD)) Phase 1/Phase 2
Terminated NCT04107675 - A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4) Phase 2
Recruiting NCT06462365 - Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) Phase 1
Completed NCT04884204 - Systematic Symptom Identification With Disease Specific PROM to Assess Symptoms of Chronic GVHD in Outpatient Care in Patients Post HSCT N/A
Completed NCT04930562 - Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD) Phase 2